Barclays Capital rated Overweight JAZZ PHARMA INC (NASDAQ: JAZZ) on 12/09/2011. Previously Barclays Capital rated Overweight JAZZ PHARMA INC (NASDAQ: JAZZ) on 06/15/2010., when the stock price was $8.52. Since then, JAZZ PHARMA INC has gained 1904.34% as of 11/25/2015's recent price of $170.77.
If you would have followed the previous Barclays Capital's recommendation on JAZZ, you would have gained 1904.34% of your investment in 1989 days.

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products to meet unmet medical needs in neurology and psychiatry. The marketed products and late-stage product candidate of the Company include Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) extended-release capsules and JZP-6 (sodium oxybate). The other product candidates in clinical development are JZP-8 (intranasal clonazepam), being developed for the treatment of recurrent acute repetitive seizures in epilepsy patients who continue to have seizures while on stable anti-epileptic regimens, JZP-4 (sodium and calcium channel antagonist), being developed for the treatment of epilepsy and bipolar disorder, and JZP-7 (ropinirole gel), being developed for the treatment of restless legs syndrome.

Barclays Capital has assembled a world-class, award-winning team of analysts covering, credit, commodities, economics, emerging markets, equities, fixed income, foreign exchange and market strategy. We provide in-depth analysis of companies and macro coverage across asset classes, markets and the world’s economies. We have a highly quantitative approach and our research is underpinned by sophisticated analytics. Combined, these provide clients with the tools and insights necessary for successful risk management and financing. Our research teams are based in many of the world’s major financial centres providing our clients with a globally integrated perspective across products and geographies.

Marked as spam